NASDAQ:IMMU
Delisted
Immunomedics Stock News
$87.86
+0 (+0%)
At Close: May 27, 2022
Should Investors Consider This Biotech Takeover Target?
11:55am, Monday, 21'st Dec 2020
Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused product line
Top 3rd-Quarter Buys of Steven Cohen's Firm
04:44pm, Friday, 27'th Nov 2020
Steven Cohen (Trades, Portfolio)'s Point72 Asset Management recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.
Should You Buy Immunomedics Before the Gilead Sciences Acquisition Closes?
07:09am, Wednesday, 28'th Oct 2020
The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.
Immunomedics, Inc. (NASDAQ:IMMU) Receives $45.38 Average Target Price from Brokerages
06:00am, Thursday, 15'th Oct 2020
Shares of Immunomedics, Inc. (NASDAQ:IMMU) have received a consensus rating of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. Eight investment an
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer
12:00am, Wednesday, 14'th Oct 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (
The Best Of The Rest: Top 50 Q3 Stocks Outside S&P 1500 (NYSEARCA:VTI)
01:41pm, Thursday, 08'th Oct 2020
In a series of recent articles, I have covered the top 50 stocks in the large-cap S&P 500, the mid-cap S&P 400, and the small-cap S&P 600.
Oct 01, 2020 (CDN Newswire via Comtex) --
This Antibody Drug Conjugates (ADC) Market research report is a broad synopsis on the study of industry and its...
Gilead Makes A Sizeable Bet On Immunomedics (NASDAQ:GILD)
12:30pm, Saturday, 26'th Sep 2020
GILD recently acquired IMMU for $21 billion. IMMU's Trodelvy has strong efficacy with metastatic triple-negative breast cancer.
Gilead Sciences: Debt Fueled Bottom (NASDAQ:GILD)
08:02am, Friday, 25'th Sep 2020
Gilead Sciences paid a hefty premium for Immunomedics. The breast cancer drug deal is expected to be accretive to EPS by 2023.
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
12:00am, Thursday, 24'th Sep 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an un
Immunomedics, Inc. (NASDAQ:IMMU) Shares Acquired by Canada Pension Plan Investment Board
08:06am, Wednesday, 23'rd Sep 2020
Canada Pension Plan Investment Board grew its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 1,511.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
03:00pm, Saturday, 19'th Sep 2020
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer | MarketScreener
02:31pm, Saturday, 19'th Sep 2020Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
02:30pm, Saturday, 19'th Sep 2020
Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard
